TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02095795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological Rehabilitation
Description: The Lokomat (Hocoma, Zurich, Switzerland) is robotic device conformed as an exoskeleton on the lower limbs of the patient. Through active and passive actuators, it realize a proper trajectory with an associated motion profile of the involved limbs. The results are physically guide repetitive, rhythmic, bilateral lower extremity movements in order to simulate a physiological gait cycle.The system uses a dynamic body weight-support system to support the participant above a motorized treadmill synchronized with the Lokomat. Participants were provided verbal encouragement to actively step in conjunction with the movement presented by the Lokomat.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Rehabilitation
Description: When needed, more than one therapist are employed in the intervention for safety reasons.
Study: NCT02508922

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2,000iu vitamin D drops will be taken daily for 20 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo drops will be taken daily for 20 weeks
Study: NCT02733302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hope theory
Description: Adapted Physical Activity
Study: NCT03278886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose naltrexone
Description: 4.5 mg of low dose naltrexone taken once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: 18 mg of nalmefene taken once daily for 8 weeks
Study: NCT01864863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1206
Description: One Bosentan 125 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1206
Description: One Bosentan 125 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traclear
Description: Two Bosentan 62.5 mg tablets
Study: NCT03677323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanyl
Description: Venous administration of 5 μg of Sufentanyl.
Study: NCT03785912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based self-help
Description: Eight cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of adjustment problems after having an accident.
Study: NCT00534885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Healive® Lot 1
Description: Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Healive® Lot 2
Description: Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Healive® Lot 3
Description: Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: Inactivated hepatitis A vaccine manufactured by GlaxoSmithKline Biologicals; two-dose regimen with 6 months apart
Study: NCT03440307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face Meetings
Description: Participants received health and fitness education, and a face-to-face 3-week intervention to reduce bisphenol exposure.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Email Only
Description: Participants received health and fitness education.
Study: NCT00039494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally
Study: NCT04525079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P59
Description: CT-P59 will be administered
Study: NCT01864863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traclear
Description: Two Bosentan 62.5 mg tablets
Study: NCT02390843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: The starting dose of simvastatin will be 140 mg/m\^2/dose BID for 21 days for the first group. Dose escalation for subsequent groups will be 180 mg/m\^2/dose BID, 225 mg/m\^2/dose BID, and 290 mg/m\^2/dose BID. If the maximum tolerated dose (MTD) has been exceeded at the first dose level, then the subsequent cohort of subjects will be treated at a dose of 100 mg/m2/dose BID (dose level 0). Simvastatin will be administered orally twice daily, approximately 12 hours apart. Feeding tube (nasogastric tube or gastrostomy tube, NOT a jejunum localized tube) administration is allowed. If a subject vomits a dose of simvastatin, it will not be repeated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The dose of cyclophosphamide will be fixed at 250 mg/m\^2/dose. Cyclophosphamide will be administered intravenously over 30 minutes once daily for 5 days every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: The dose of topotecan will be fixed at 0.75 mg/m\^2/dose. Topotecan will be administered, after cyclophosphamide, intravenously over 30 minutes once daily for 5 days every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myeloid growth factor
Description: Myeloid growth factor (G-CSF or pegylated G-CSF) will be initiated 24-48 hours after the completion of topotecan and cyclophosphamide for all subjects, which would be day 6 or 7. Myeloid growth factor should continue until the absolute neutrophil count is greater than 2,000/mm\^3
Study: NCT01798186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will be exposed to cannabis smoke present in ambient air

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will be exposed to cannabis smoke present in ambient air

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will be exposed to cannabis smoke present in ambient air
Study: NCT01474616

Intervention type: OTHER
Group type: OTHER
Intervention: Sit-to-Stand Activity
Description: Health care aides will be expected to prompt residents to repeatedly stand up and sit down on four occasions throughout the day (twice on each of the day and evening shifts). The number of repetitions on each occasion will vary according to residents' ability and fatigue. The sit-to-stand activity is to be integrated into usual care routines such as when entering the dining room at mealtimes, while toileting, and on other occasions of regular activity. The timing and location will be at the discretion of the health care aide.
Study: NCT00790153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin infusion given during 3 hours at one occasion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1656
Description: Single dose oral suspension given at one occasion.
Study: NCT02735733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Bakri Balloon
Description: In the room temperature arm, the bakri balloon will be inserted through the vagina and placed inside the uterus and filled with room temperature saline. In the cold arm, the same intervention will performed, however, the bakri balloon will be filled with cold saline at 32 degrees Fahrenheit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Bakri Balloon
Description: In the room temperature arm, the bakri balloon will be inserted through the vagina and placed inside the uterus and filled with room temperature saline. In the cold arm, the same intervention will performed, however, the bakri balloon will be filled with cold saline at 32 degrees Fahrenheit.
Study: NCT03740880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual trigger
Description: dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual trigger
Description: dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca
Study: NCT01113658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNaP Wound Care System
Description: The intervention is negative pressure wound therapy (NPWT) with the Spiracur SNaP Wound Care system for the treatment of a variety of acute and chronic wounds including pressure ulcers, trauma wounds, diabetic foot ulcers, venous stasis ulcers, and skin grafts.~The Spiracur SNaP Wound Care system weighs less than 4 ounces, does not utilize an electric pump (device has no electrically powered parts), is fully disposable after use, and is designed for particularly small chronic wounds that require advanced wound care management. It delivers NPWT at a constant pressure level over several days without any required adjustments by the patient or clinician.
Study: NCT00708305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride (NaF)
Description: Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride (NaF)
Description: Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride (NaF)
Description: Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fluoride free toothpaste (0ppmF)
Study: NCT04711460

Intervention type: BEHAVIORAL
Intervention: Younger participants
Description: Younger Participants 19-29 years received TAU + Tx over 5 weeks

Intervention type: BEHAVIORAL
Intervention: Older participants
Description: older participants 30-54 years received TAU + Tx over 5 weeks

Intervention type: BEHAVIORAL
Intervention: TAU
Description: Participants received TAU or Treatment As Ususal, Cognitive Behavior Therapy only

Intervention type: BEHAVIORAL
Intervention: TAU + MIndfulness practice
Description: Participants received TAU + mindfulness training
Study: NCT04942860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Methotrexate gel
Description: 1% methotrexate gel applied onto a predefined limb

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% Methotrexate gel
Description: 1% methotrexate gel applied onto a predefined limb

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Methotrexate gel
Description: 0.5% methotrexate gel applied onto a predefined limb

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.5% Methotrexate gel
Description: 0.5% methotrexate gel applied onto a predefined limb
Study: NCT04147182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline 3%
Description: 3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. The pH may have been adjusted with hydrochloric acid. It contains no antimicrobial agents.
Study: NCT00624325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: 12 MU daily continuously subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: 9 MU daily continuously subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon alfa-2b
Description: 6 MU daily continuously subcutaneous
Study: NCT03173781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: droxidopa
Description: medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: medication
Study: NCT02490618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic tablet- Biogaia
Study: NCT04525079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P59
Description: CT-P59 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P59
Description: CT-P59 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-P59
Description: CT-P59 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching CT-P59

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching CT-P59

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching CT-P59

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching CT-P59
Study: NCT01413789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermatix
Description: 1 application of Dermatix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kelocote
Description: 1 application of Kelocote

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAP scar gel
Description: 1 application of BAP scar gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alhydran
Description: 1 application of Alhydran

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bap Scar Care T
Description: 1 application of BAP Scar Care T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bap Scar Care S
Description: 1 Application of Bap Scar Care S

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepiform
Description: 1 application of Mepiform

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scar Ban Elastic
Description: 1 application of Scar Ban Elastic
Study: NCT03231540

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplement
Description: Whey protein supplement to target protein intake of 1.5 g/kg/day
Study: NCT03819595

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise
Description: a free 12-week, small-group (\~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: a free 12-week, small-group (\~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Program PVS
Description: a standardized promotion prescription of physical activity, balanced diet and smoking cessation, using the computer tool Promote Healthy Living integrated into the electronic medical record.
Study: NCT02490618

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Study: NCT00282815

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure or CPAP
Description: RemStar Pro (Respironics, Inc.) The CPAP is applied through a nasal mask during the hours of sleep. Positive air pressure holds the naso-oro-pharyngeal airway open during sleep.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham CPAP
Description: sham CPAP
Study: NCT03239405

Intervention type: DEVICE
Intervention: Suction callibrated system
Description: One-step suction callibrated SG system
Study: NCT01921244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Parents will receive an intervention modified from the previously published tool called Autism: Should My Child Take Medicine for Challenging Behavior? This packet provides parents with educational information, elicits parent ratings of particular behavioral domains, describes behaviors that are and are not amenable to medication treatment, and elicits parent preferences regarding treatment. Providers will be trained on use of the intervention in practice to promote shared decision making during clinical encounters.
Study: NCT01808976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: this is a mobile app that participants use to solve problems. It will guide participants through a stepwise process for identifying a means for creating action plans.
Study: NCT02108483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel
Description: Patches containing dapsone gel will be applied to the skin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel vehicle
Description: Patches containing dapsone gel vehicle will be applied to the skin.
Study: NCT01808976

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evolution
Description: This is a therapeutic video game that targets the cognitive control network, associated with depression. Participants are expected to play the game daily for 20 minutes over 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic health push app
Description: This is an app that send daily tips for improving your mood.
Study: NCT03424486

Intervention type: OTHER
Intervention: Questionnaires
Description: Evaluation of the prevalence of anxiety, depression and quality of life

Intervention type: OTHER
Intervention: Questionnaires
Description: Evaluation of the prevalence of anxiety, depression and quality of life
Study: NCT02489825

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Augmentation vertebroplasty
Description: Cement augmentation of fractured vertebral body

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Augmentation and prophylactic vertebroplasty
Description: Cement augmentation of fractured vertebral body and prophylactic augmentation of both adjacent vertebral bodies
Study: NCT03984032

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Protector Cuff Pilot
Description: Assessing the clinical performance of LMA Protector Cuff Pilot

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Description: Assessing the clinical performance of LMA Supreme
Study: NCT04023097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothwave toothbrush
Description: Subjects get the device's box with the user manual and the device. However, they don't use the device, but only read the user manual and fill questionnaires.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothwave toothbrush
Description: Subjects get the device's box with the user manual and the device. However, they don't use the device, but only read the user manual and fill questionnaires.
Study: NCT04071119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Participants administer the oxytocin (40 IU) twice a day for 5 - 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants administer the placebo (40 IU) twice a day for 5 - 7 days
Study: NCT04506996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management
Description: see arm/group descriptions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monday-Focused Written Messages for Weight Management
Description: see arm/group descriptions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Materials
Description: After the baseline assessment and the 1st follow-up (\~8 weeks post randomization), participants received educational materials regarding physical activity and healthier diets. The study staff reviewed these materials with the participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: After the baseline assessment and the 1st follow-up (\~8 weeks post randomization), participants received educational materials regarding physical activity and healthier diets. The study staff reviewed these materials with the participants
Study: NCT01113619

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RP-G28 or placebo
Description: Qualified subjects randomized to daily dosing with RP-G28 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-G28 or placebo
Description: Qualified subjects randomized to daily dosing with RP-G28 or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RP-G28 or placebo
Description: Daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-G28 or placebo
Description: Daily dosing
Study: NCT03900377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB L-0501RI
Description: The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB L-0501RI
Description: The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.
Study: NCT02247804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Description: Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Description: Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator: Timolol 0.5%
Description: Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator: Timolol 0.5%
Description: Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Timolol 0.5%
Description: Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham: Applicator Without Needle
Description: Sham administered on Day 1, Week 16, and Week 32.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham: Applicator Without Needle
Description: Sham administered on Day 1, Week 16, and Week 32.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham: Applicator Without Needle
Description: Sham administered on Day 1, Week 16, and Week 32.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Vehicle (placebo)
Description: Timolol vehicle administered once in the morning and once in the evening for up to 20 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Vehicle (placebo)
Description: Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
Study: NCT01646684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230